BlackRock’s AC Immune ACIU Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.24M | Sell |
519,274
-5,004
| -1% | -$13.8K | ﹤0.01% | 4292 |
|
|
2026
Q1 | $1.44M | Buy |
524,278
+22,109
| +4% | +$68.7K | ﹤0.01% | 4223 |
|
|
2025
Q4 | $1.58M | Buy |
502,169
+90,321
| +22% | +$285K | ﹤0.01% | 4187 |
|
|
2025
Q3 | $1.19M | Buy |
411,848
+541
| +0.1% | +$1.22K | ﹤0.01% | 4242 |
|
|
2025
Q2 | $835K | Sell |
411,307
-745,284
| -64% | -$1.3M | ﹤0.01% | 4310 |
|
|
2025
Q1 | $2.16M | Sell |
1,156,591
-1,055,931
| -48% | -$2.66M | ﹤0.01% | 3972 |
|
|
2024
Q4 | $5.97M | Sell |
2,212,522
-461,789
| -17% | -$1.44M | ﹤0.01% | 3652 |
|
|
2024
Q3 | $10.1M | Buy |
2,674,311
+66,880
| +3% | +$234K | ﹤0.01% | 3403 |
|
|
2024
Q2 | $10.4M | Buy |
2,607,431
+65,479
| +3% | +$217K | ﹤0.01% | 3368 |
|
|
2024
Q1 | $7.52M | Buy |
2,541,952
+123,932
| +5% | +$444K | ﹤0.01% | 3498 |
|
|
2023
Q4 | $12.1M | Buy |
2,418,020
+2,414,002
| +60,080% | +$7.76M | ﹤0.01% | 3292 |
|
|
2023
Q3 | $11.5K | Hold |
4,018
| – | – | ﹤0.01% | 5191 |
|
|
2023
Q2 | $11.9K | Hold |
4,018
| – | – | ﹤0.01% | 5241 |
|
|
2023
Q1 | $9.4K | Hold |
4,018
| – | – | ﹤0.01% | 5331 |
|
|
2022
Q4 | $8.2K | Sell |
4,018
-363,975
| -99% | -$938K | ﹤0.01% | 5485 |
|
|
2022
Q3 | $1.16M | Sell |
367,993
-10,239
| -3% | -$32.3K | ﹤0.01% | 4427 |
|
|
2022
Q2 | $1.37M | Buy |
378,232
+85,959
| +29% | +$294K | ﹤0.01% | 4403 |
|
|
2022
Q1 | $1.17M | Buy |
292,273
+4,685
| +2% | +$20.3K | ﹤0.01% | 4614 |
|
|
2021
Q4 | $1.42M | Sell |
287,588
-19,643
| -6% | -$114K | ﹤0.01% | 4538 |
|
|
2021
Q3 | $2.06M | Sell |
307,231
-41,232
| -12% | -$295K | ﹤0.01% | 4313 |
|
|
2021
Q2 | $2.76M | Sell |
348,463
-276,654
| -44% | -$1.91M | ﹤0.01% | 4132 |
|
|
2021
Q1 | $4.76M | Sell |
625,117
-31,038
| -5% | -$222K | ﹤0.01% | 3964 |
|
|
2020
Q4 | $3.39M | Sell |
656,155
-38,867
| -6% | -$198K | ﹤0.01% | 3856 |
|
|
2020
Q3 | $3.39M | Sell |
695,022
-60,432
| -8% | -$434K | ﹤0.01% | 3738 |
|
|
2020
Q2 | $5.08M | Buy |
755,454
+164,424
| +28% | +$1.19M | ﹤0.01% | 3515 |
|
|
2020
Q1 | $4.08M | Sell |
591,030
-32,052
| -5% | -$251K | ﹤0.01% | 3437 |
|
|
2019
Q4 | $5.31M | Sell |
623,082
-39,093
| -6% | -$261K | ﹤0.01% | 3481 |
|
|
2019
Q3 | $3.28M | Sell |
662,175
-10,413
| -2% | -$55.8K | ﹤0.01% | 3603 |
|
|
2019
Q2 | $3.73M | Sell |
672,588
-25,414
| -4% | -$130K | ﹤0.01% | 3605 |
|
|
2019
Q1 | $3.52M | Buy |
698,002
+53,327
| +8% | +$339K | ﹤0.01% | 3530 |
|
|
2018
Q4 | $6.09M | Buy |
+644,675
| New | +$6.09M | ﹤0.01% | 3325 |
|
Other funds holding ACIU
BlackRock's ACIU Position: Q2 2026 in Review
BlackRock reduced its AC Immune (ACIU) stake by 0.95% in Q2 2026, selling an estimated $13.8K and leaving 519,274 shares worth $1.24M. The position accounts for ﹤0.01% of the portfolio, ranked #4292.
BlackRock first reported a position in ACIU in Q4 2018 and has held it in 31 quarters since. The position peaked at $12.1M in Q4 2023. 40 funds tracked by Wall St. Rank hold ACIU as of Q2 2026.
- BlackRock held 519,274 shares of AC Immune worth $1.24M as of Q2 2026.
- BlackRock sold 5,004 AC Immune shares in Q2 2026, an estimated $13.8K.
- AC Immune made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #4292 holding.
- BlackRock first reported a position in AC Immune in Q4 2018 and has held it in 31 quarters since.
- BlackRock's AC Immune position peaked at $12.1M in Q4 2023.
- 40 funds tracked by Wall St. Rank held AC Immune as of Q2 2026.
Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.